Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in gastric and GEJ adenocarcinoma
NCT03221426Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2017
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Merck & Co. Primary endpoints: Event-free Survival at 75 months, Pathological Complete Response Rate at 18 weeks and 3 more. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03221426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221426.